Horizon Pharma announced an additional analysis of data from the pivotal Circadian Administration of Prednisone in Rheumatoid Arthritis-2, or CAPRA- 2, trial demonstrating that patients with active rheumatoid arthritis, or RA, treated with its recently approved RAYOS 5 mg delayed-release tablets who met ACR20, DAS28 and HAQ-DI response criteria had a significantly greater reduction in morning stiffness than patients who didn't meet these criteria. Data were presented during the American College of Rheumatology, or ACR/Association of Rheumatology Health Professionals, or ARHP, Annual Scientific Meeting in Washington, D.C. Results from these analyses demonstrated that morning stiffness duration, morning stiffness severity and pain intensity upon awakening correlated with DAS28 and HAQ-DI in all treatment group analyses. There were stronger absolute correlations seen with morning stiffness severity and pain intensity upon awakening than with morning stiffness duration, whether the treatment groups were analyzed separately or together. Patients who met ACR20, DAS28 and HAQ-DI response criteria had a greater relative reduction in morning stiffness than patients who didn't meet these criteria. There were no safety concerns for RAYOS 5 mg shown in the study beyond those already established for immediate-release prednisone.